AVADEL PHARMACEUTICALS PLCAVDLEarnings & Financial Report
Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
AVDL Q3 FY2025 Key Financial Metrics
Revenue
$77.5M
Gross Profit
$81.6M
Operating Profit
$1.9M
Net Profit
$20.0K
Gross Margin
105.3%
Operating Margin
2.5%
Net Margin
0.0%
YoY Growth
54.9%
EPS
$0.00
AVADEL PHARMACEUTICALS PLC Q3 FY2025 Financial Summary
AVADEL PHARMACEUTICALS PLC reported revenue of $77.5M (up 54.9% YoY) for Q3 FY2025, with a net profit of $20.0K (up 100.8% YoY) (0.0% margin).
Key Financial Metrics
| Total Revenue | $77.5M |
|---|---|
| Net Profit | $20.0K |
| Gross Margin | N/A |
| Operating Margin | 2.5% |
| Report Period | Q3 FY2025 |
AVADEL PHARMACEUTICALS PLC Annual Revenue by Year
AVADEL PHARMACEUTICALS PLC annual revenue history includes year-by-year totals (for example, 2024 revenue was $169.1M).
AVADEL PHARMACEUTICALS PLC Quarterly Revenue & Net Profit History
AVADEL PHARMACEUTICALS PLC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $77.5M | +54.9% | $20.0K | 0.0% |
| Q2 FY2025 | $68.1M | +64.2% | $9.7M | 14.2% |
| Q1 FY2025 | $52.5M | +93.2% | $-4.9M | -9.4% |
| Q4 FY2024 | $50.4M | +159.1% | $-5.0M | -10.0% |
| Q3 FY2024 | $50.0M | +613.2% | $-2.6M | -5.2% |
| Q2 FY2024 | $41.5M | +2674.3% | $-13.8M | -33.3% |
| Q1 FY2024 | $27.2M | — | $-27.3M | -100.6% |
| Q4 FY2023 | $19.5M | — | $-28.8M | -148.0% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $27.2M | $41.5M | $50.0M | $50.4M | $52.5M | $68.1M | $77.5M |
| YoY Growth | N/A | N/A | 2674.3% | 613.2% | 159.1% | 93.2% | 64.2% | 54.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $164.7M | $167.9M | $157.5M | $158.3M | $164.2M | $167.9M | $187.2M | $199.4M |
| Liabilities | $77.0M | $89.5M | $87.2M | $83.6M | $90.4M | $93.9M | $96.4M | $101.2M |
| Equity | $87.7M | $78.4M | $70.3M | $74.7M | $73.8M | $74.1M | $90.7M | $98.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-28.0M | $-29.7M | $-18.2M | $-6.9M | $7.9M | $-8.2M | $12.7M | $22.2M |